Myriad Genetics Shareholder Alert: Bernstein Liebhard LLP Announces That A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. – MYGN

April 23, 2018

Responsive image

NEW YORK, April 23, 2018 /PRNewswire/ — Bernstein Liebhard LLP announces that a class action lawsuit has been filed on behalf of purchasers of the securities of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) between August 13, 2014 and March 12, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Myriad Genetics investors under the federal securities laws.

To join the Myriad Genetics class action, and/or if you have information relating to this matter,  please visit www.bernlieb.com/Myriad_Genetics or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

According to the lawsuit, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (2) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (3) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (4) as a result, Myriad’s public statements were materially false and misleading at all relevant times.

On March 12, 2018, during aftermarket hours, Myriad disclosed that it had received a subpoena from the U.S. Department of Health and Human Services, Office of Inspector General, in connection with “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to Myriad’s hereditary cancer testing. The subpoena covers a time period from January 1, 2014—less  than four months after the September 2013 launch of Myriad’s myRisk cancer test—through the date of the subpoena’s issuance. On this news, Myriad’s stock fell $4.01, or 12.14%, to close at $29.01 on March 13, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than June 19, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

Please follow us for updates on LinkedIn: https://www.linkedin.com/company/bernstein-liebhard-llp/ and Twitter: https://twitter.com/bernlieb.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com 
(877) 779-1414
dsadeh@bernlieb.com

View original content with multimedia:http://www.prnewswire.com/news-releases/myriad-genetics-shareholder-alert-bernstein-liebhard-llp-announces-that-a-class-action-lawsuit-has-been-filed-against-myriad-genetics-inc—mygn-300634664.html

SOURCE Bernstein Liebhard LLP

Related Links

http://www.bernlieb.com

Category: Precious Metals